EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction

Positive

AI Analysis

Summary

EpiVax announced AI-enhanced updates to its ISPRI platform, including an updated JanusMatrix model for assessing immunogenicity risk in biotherapeutics. This represents a product development milestone for the company's in silico prediction technology.

Importance:2/10

Sentiment:

0.60

AI/Machine LearningImmunogenicityPlatform TechnologyBiotherapeutics

Read the original article

Published by PR Newswire Biotech on September 2, 2026 3:16 PM

Read Original